Finding ways to counteract the dangerous effects of fentanyl-xylazine mixtures.
Official title: Counteracting cardiorespiratory and subjective effects of fentanyl-xylazine mixtures using a dual antagonist approach
Funded at Rowan University School/osteopathic Med · NIH-11038517 · Data updated 2026-11-12
This study is looking into how dangerous mixtures of fentanyl and xylazine affect breathing and heart health, with the goal of finding better ways to treat overdoses and keep people safer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rowan University School/osteopathic Med NIH-funded |
| Lab location | 1 site (Stratford, United States) |
| Project start | September 30, 2024 |
| Project end | September 29, 2026 |
| Funding year | 2024 |
| Award (this year) | $423,708 |
| NIH project number | 1R21DA062164-01 |
| Project ID | NIH-11038517 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have been exposed to or are at risk of exposure to fentanyl-xylazine mixtures.
✕Less likely to help
Patients who do not use or are not at risk of using fentanyl-xylazine mixtures may not receive any benefit from this research.
What this research studies
This research investigates the harmful effects of fentanyl-xylazine mixtures, which have become increasingly common in the illicit drug supply. The study aims to understand how these mixtures affect breathing and heart function, as they can lead to severe health risks, including overdose. By using a dual antagonist approach, the research seeks to develop effective treatments that can reverse the dangerous effects of these substances. Patients may benefit from improved safety measures and treatment options if successful.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively counteract the life-threatening effects of fentanyl-xylazine mixtures.
How similar studies have gone: While there is ongoing research into opioid antagonists, the specific approach to counteract fentanyl-xylazine mixtures is relatively novel and has not been extensively tested.
Where this research is happening
-
Rowan University School/osteopathic Med
Stratford, United States Active
Researchers
- Principal investigator: Manvich, Daniel F. — Rowan University School/osteopathic Med
- Study coordinator: Manvich, Daniel F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.